CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
MEDI4736 + tremelimumab +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02340975
NCT02340975Phase 2Completed
CompareCT.gov

A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

MedImmune LLC·interventional·Posted Jan 19, 2015·Updated Jun 9, 2020

In Brief

A Phase 2 clinical trial evaluating MEDI4736 + tremelimumab, MEDI4736, and 2 other interventions for Gastric or Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 114 participants across 28 sites in 6 countries.

Detailed Summary

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric or Gastroesophageal Junction Adenocarcinoma
CountriesCanada, Japan, Singapore, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 19, 2015
Enrollment StartMar 31, 2015
Primary CompletionApr 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.5 years ago

Interventions

MEDI4736 + tremelimumabbiological

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

MEDI4736 + tremelimumabbiological

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

MEDI4736biological

MEDI4736 will be administered by IV infusion.

Tremelimumabbiological

Tremelimumab will be administered by IV infusion.

MEDI4736+tremelimumabbiological

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

MEDI4736 + tremelimumabbiological

MEDI4736 will be administered by IV infusion in combination with tremelimumab.